Skip to contentN
NovoCure Ltd
N
NVCRNovoCure Ltd Q3 2021 · 10-Q
Revenue$133.61M$133.61M+0.7% vs Q3 2020 Net Income-$13.12M-$13.12MN/M vs Q3 2020 EPS Diluted-$0.13-$0.13N/M vs Q3 2020 Gross Profit$103,400,000−0.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
NovoCure Ltd · CIK 1645113 · Engraved from SEC EDGAR
Operating Cash Flow$24,400,000−21.2% Free Cash Flowderived$21,103,000−25.1% Margins · derivedGross margin77.4%−1.2 pt vs Q3 2020
Operating margin-6.4%−17.7 pt vs Q3 2020
Net margin-9.8%−16.8 pt vs Q3 2020
ended Sep 30, 2021 · filed Oct 28, 2021 · 28 d after period end